Tag

Avidity Biosciences

All articles tagged with #avidity biosciences

business23 hours ago•2 min saved

Atrium Therapeutics spins out from Novartis-Avidity deal with two cardio RNA therapies

Atrium Therapeutics, a spinout formed from Novartis's $12 billion acquisition of Avidity Biosciences, debuts with $270 million in cash and two preclinical RNA interference assets (ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy). Led by Kathleen Gallagher, Atrium plans a Phase 1 trial for ATR 1072 in the second half of this year and for ATR 1086 in 2027, with the new ticker RNAM, inheriting Avidity's market position.

via Fierce Biotech|

#atrium-therapeutics #avidity-biosciences #business

business4 months ago•0 min saved

Novartis's $12B Avidity Deal Boosts Biotech Stocks and Neuroscience Pipeline

Novartis' CEO indicated that their $12 billion acquisition of Avidity BioSciences could have been twice as large, highlighting the significance of timing in deal-making.

via Endpoints News|

#acquisition #avidity-biosciences #biotech

business4 months ago•3 min saved

Novartis Nears $12 Billion Deal to Acquire Avidity Biosciences

Novartis is acquiring Avidity Biosciences for about $12 billion to expand its portfolio in rare muscle disorders and strengthen its US presence, with Avidity's early-stage cardiology programs to be spun off into a new company, Spinco.

via Reuters|

#acquisition #avidity-biosciences #biotech

business4 months ago•11 min saved

Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Neuroscience Pipeline

Novartis plans to acquire Avidity Biosciences for $12 billion to strengthen its neuroscience pipeline with late-stage RNA therapeutics targeting neuromuscular diseases, including a new platform for muscle-directed delivery of RNA therapies, aiming for product launches before 2030 and increasing its sales growth forecast to 6% CAGR for 2024-2029.

via Novartis|

#acquisition #avidity-biosciences #business

business4 months ago•1 min saved

Novartis Approaches $12 Billion Acquisition of Avidity Biosciences

Novartis is set to acquire Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry.

via Financial Times|

#acquisition #avidity-biosciences #business

business4 months ago•1 min saved

Novartis to Acquire Avidity Biosciences for $12 Billion in Cash

Novartis is acquiring U.S. biotech firm Avidity Biosciences for about $12 billion in cash, aiming to expand its RNA therapeutics portfolio and boost growth, with the deal expected to close in the first half of 2026 after Avidity spins out some of its business units.

via CNBC|

#acquisition #avidity-biosciences #biotech

business4 months ago•1 min saved

Novartis Nears $10 Billion Deal to Acquire Avidity Biosciences

Novartis is close to acquiring Avidity Biosciences for over $70 per share, in a deal potentially valued at around $6.8 billion, aiming to strengthen its portfolio amid a wave of biotech M&A and upcoming patent expirations.

via Bloomberg.com|

#avidity-biosciences #biotechnology #business